Home » Topics » Regulatory » EMA

EMA
RSS

Obeticholic acid receives E.U. orphan drug status for primary biliary cirrhosis

Aug. 10, 2010

Celgene's pomalidomide receives E.U. orphan drug status for myelofibrosis

Aug. 10, 2010

EMA's CHMP issues positive opinion on Relistor in prefilled syringes

Aug. 6, 2010

COMP recommends orphan drug status for XOMA-052 in Behcet's disease

July 30, 2010

Bionovo moves Menerba to phase III testing in Europe

July 30, 2010

CHMP issues positive opinion on Arixtra use for superficial vein thrombosis

July 27, 2010

CHMP issues positive opinion on Twynsta for hypertension

July 26, 2010

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

July 26, 2010

EMA recommends restricting modafinil use

July 26, 2010

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

July 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.